Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324570 · ClinicalTrials.gov registry record · Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children
A Phase 3 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT01324570 is a Phase 3 study that has completed, run by Purdue Pharma. The registered enrollment target is 41 participants.
The verdict
NCT01324570, a Phase 3 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, PK, and efficacy of BTDS in patients of ages 7 to 16 years.
Interventions
- DRUG Buprenorphine transdermal system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324570
The ClinicalTrials.gov registry entry for NCT01324570 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine transdermal system is the first listed.
NCT01324570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324570 about?
NCT01324570 is a clinical study titled "Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children". The purpose of this study is to characterize the safety, PK, and efficacy of BTDS in patients of ages 7 to 16 years.
What is the current status of trial NCT01324570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2011-07. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01324570?
The interventions under investigation include: Buprenorphine transdermal system (DRUG).
Who is sponsoring clinical trial NCT01324570?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.